Cargando…
Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
SIMPLE SUMMARY: Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy has emerged as a new life-saving treatment modality in patients with relapsed or refractory B-cell malignancies and multiple-myeloma. In this form of therapy, patient’s T-cells are modified by various genetic techniques to expres...
Autores principales: | Sharma, Naman, Reagan, Patrick M., Liesveld, Jane L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946106/ https://www.ncbi.nlm.nih.gov/pubmed/35326654 http://dx.doi.org/10.3390/cancers14061501 |
Ejemplares similares
-
How I treat cytopenias after CAR T-cell therapy
por: Jain, Tania, et al.
Publicado: (2023) -
PB2314: CYTOPENIAS AND BLOOD TRANSFUSION SUPPORT AFTER CAR-T THERAPY
por: Rivada, Marcos, et al.
Publicado: (2023) -
CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
por: Taneja, Alankrita, et al.
Publicado: (2021) -
Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
por: Xing, Limin, et al.
Publicado: (2021) -
NPM 1 Mutations in AML—The Landscape in 2023
por: Sharma, Naman, et al.
Publicado: (2023)